Express News | Viracta Therapeutics Inc: Appointed Craig Jalbert as CEO, CFO, Sole Member of Board to Implement Wind Down

ReutersFeb 5 17:01 ET

Viracta Therapeutics Announces Wind Down of Operations

GlobeNewswireFeb 5 17:00 ET

Why Triumph Group Shares Are Trading Higher By Over 36%; Here Are 20 Stocks Moving Premarket

BenzingaFeb 3 06:10 ET

12 Health Care Stocks Moving In Friday's Pre-Market Session

BenzingaDec 27, 2024 16:05 ET

Deal Dispatch: Party City Wraps Up, Big Lots Goes Bust, The Container Store Continues

BenzingaDec 27, 2024 15:44 ET

Masimo To Rally More Than 13%? Here Are 5 Top Analyst Forecasts For Friday

BenzingaDec 27, 2024 09:03 ET

Rodman & Renshaw Downgrades Viracta Therapeutics(VIRX.US) to Hold Rating, Cuts Target Price to $0.25

Moomoo NewsDec 27, 2024 07:31 ET · Ratings

Rodman & Renshaw Downgrades Viracta Therapeutics to Neutral

MT NewswiresDec 27, 2024 07:08 ET

Constellium, Viracta Therapeutics And 3 Stocks To Watch Heading Into Friday

BenzingaDec 27, 2024 03:41 ET

Stocks to Watch: Grid Dynamics, Viracta Therapeutics, Martin Midstream

WSJDec 26, 2024 18:38 ET

Viracta Therapeutics Ends Naval-1 Clinical Trial and Is Exploring Strategic Alternatives

WSJDec 26, 2024 17:02 ET

Express News | Viracta Therapeutics Inc - Potential Alternatives Include Merger, Licensing Agreement, Sale

ReutersDec 26, 2024 16:30 ET

Express News | Viracta Therapeutics Inc - Closure of Trial Not Due to New Safety Finding

ReutersDec 26, 2024 16:30 ET

Express News | Viracta Therapeutics Announces Closure of Naval-1 Clinical Trial and Exploration of Strategic Alternatives

ReutersDec 26, 2024 16:30 ET

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

BenzingaDec 4, 2024 16:06 ET

Trending Stocks Today | CN Energy Surges 94.04% Pre-Market

Moomoo NewsDec 4, 2024 05:20 ET

Why Marvell Technology Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket

BenzingaDec 4, 2024 05:11 ET

Express News | Viracta Therapeutics Inc - Receives Notice of Non-Compliance From Nasdaq

ReutersNov 22, 2024 17:21 ET

Viracta Therapeutics Is Maintained at Outperform by RBC Capital

Dow JonesNov 14, 2024 12:18 ET · Ratings

RBC Cuts Price Target on Viracta Therapeutics to $2 From $4, Keeps Outperform, Speculative Risk

MT NewswiresNov 14, 2024 07:40 ET · Ratings